苯那普利上市后流行病学监测

目的 了解苯那普利在一般高血压患者中长期应用的药效及安全性。方法 对上海市某社区1831例原发性高血压患者进行为期3年的药物上市后流行病学监测。结果 3年随访74.3％的患者坚持服药,且具有理想的服药依从性。用药3年后,按规定服药者的收缩压达标率为75.7％,舒张压达标率为87.4％,总达标率为71.5％。总体收缩压水平较服药前降低了近15mm Hg(1mmHg=0.133kPa),舒张压降低了约10mmHg,脉压降低了近5mmHg。用药期间,未见有严重不良反应发生。咳嗽是该药主要的一种不良反应。3年累积咳嗽发生率,女性达23.6％,高于男性的18.8％。结论 苯那普利应用于一般高血压患者群体时,具有较好的长期效果和安全性。

Postmarketing surveillanc on Benazepril

Objective To investigate the long-term effect, safety and tolerability of benazepril in general hypertensive patients. Methods We conducted a three-year community-based postmarketing surveillance on benazepril among 1831 essential hypertensive patients (age range from 35 to 88 years) in Shanghai. Results 74. 3% of patients persisted in medication taking and were with optimal compliance in a 3-year-follow-up program. Among those taking medication as prescribed after 3 years, 75. 7% of them attained systolic blood pressure (SBP) target level of 140 mm Hg (1 mm Hg=0.133 kPa), 87 .4% attained diastolic blood pressure (DBP) target level of 90 mm Hg, and 71. 5% attained total target level of 140/90 mm Hg. The reductions were approaching 15 mm Hg for SBP, 10 mm Hg for DBP,and 5 mm Hg for pulse pressure (PP) during the 3 year period. No serious adverse drug reactions (ADRs) were detected during the 3 years folow-up. Cough was the most common ADR. The cumulative incidence of benazepril related cough was 23. 6% in women, significant higher than in men (18.8%). Conclusion Benazepril was safe and tolerable when applied in hypertensive patients.